Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer
Rosendahl AH, Perks CM, Zeng L, Markkula A, Simonsson M, Rose C, Ingvar C, Holly JM, Jernström H
Clinical cancer research : an official journal of the American Association for Cancer Research · 111 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (classified by our AI screen)
- Studied in
- People, plus animal or lab work
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2015-02-18 · Clin Cancer Res · vol. 21 · issue 8 · pp. 1877–1887
- Publisher
- American Association for Cancer Research
- Cited
- 149 citations · more than 99% of similar papers · 11.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 47 works
- Access
- Paywalled
- Research areas
- Coffee research and impacts · Cancer Risks and Factors · Tea Polyphenols and Effects
- Keywords
- Estrogen receptor, Breast cancer, Caffeine, Caffeic acid, Tamoxifen, Endocrinology, Internal medicine, Medicine, Cancer, Population, Cancer research, Chemistry, Biochemistry
- MeSH
- cell line, tumor, humans, coffea, breast neoplasms, neoplasm metastasis, neoplasm recurrence, local, caffeic acids, caffeine, receptor, igf type 1, receptors, estrogen, tumor burden, risk factors, cell cycle, cell proliferation, cell survival, adult, aged, aged, 80 and over, middle aged, female, young adult, neoplasm grading, biomarkers, tumor
9 authors
From SE, GB
- Ann H. Rosendahl · correspondingSkåne University Hospital
- Claire M. PerksSouthmead Hospital
- Li ZengSouthmead Hospital
- Andrea MarkkulaSkåne University Hospital
- Maria SimonssonSkåne University Hospital
- Carsten RoseMedicon Village
Abstract
Purpose
Epidemiologic studies indicate that dietary factors, such as coffee, may influence breast cancer and modulate hormone receptor status. The purpose of this translational study was to investigate how coffee may affect breast cancer growth in relation to estrogen receptor-α (ER) status.
Experimental design
The influence of coffee consumption on patient and tumor characteristics and disease-free survival was assessed in a population-based cohort of 1,090 patients with invasive primary breast cancer in Sweden. Cellular and molecular effects by the coffee constituents caffeine and caffeic acid were evaluated in ER(+) (MCF-7) and ER(-) (MDA-MB-231) breast cancer cells.
Results
Moderate (2-4 cups/day) to high (≥5 cups/day) coffee intake was associated with smaller invasive primary tumors (Ptrend = 0.013) and lower proportion of ER(+) tumors (Ptrend = 0.018), compared with patients with low consumption (≤1 cup/day). Moderate to high consumption was associated with lower risk for breast cancer events in tamoxifen-treated patients with ER(+) tumors (adjusted HR, 0.51; 95% confidence interval, 0.26-0.97). Caffeine and caffeic acid suppressed the growth of ER(+) (P ≤ 0.01) and ER(-) (P ≤ 0.03) cells. Caffeine significantly reduced ER and cyclin D1 abundance in ER(+) cells. Caffeine also reduced the insulin-like growth factor-I receptor (IGFIR) and pAkt levels in both ER(+) and ER(-) cells. Together, these effects resulted in impaired cell-cycle progression and enhanced cell death.
Conclusions
The clinical and experimental findings demonstrate various anticancer properties of caffeine and caffeic acid against both ER(+) and ER(-) breast cancer that may sensitize tumor cells to tamoxifen and reduce breast cancer growth.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.